A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Henney. Alex E AE; Riley. David R DR; Heague. Megan M; Roberts. Carl A CA; Hydes. Theresa J TJ; Anso...
In a huge U.S. health‑record study, people with type‑2 diabetes who started the weight‑loss drug tirzepatide (or semaglutide) were about half as likely to develop a new alcohol‑use disorder over the next 18 months compared to those on older diabetes pills. The effect was strongest for tirzepatide, which also beat liraglutide in a head‑to‑head look.
Jia. Anna A; Yang. Ming M; Wang. Tianhong T; Hua. Yusi Y; Lu. Huimin H
A meta‑analysis of six studies shows that drugs in the GLP‑1 receptor agonist family – including tirzepatide – cut the chance of heart‑failure worsening by more than half, help people lose about 8 kg, and boost exercise capacity and quality‑of‑life scores, without raising major safety worries.
Nduma. Basil B; Malapati. Sai Nikhitha SN; Vibhuti. Veeranna V
A 65‑year‑old woman on a thiazide diuretic (hydrochlorothiazide) developed dangerous high calcium levels shortly after starting tirzepatide, a new diabetes/obesity drug. Stopping both drugs, giving fluids and calcitonin fixed the problem, suggesting the two meds together can push calcium too high, especially in people with kidney issues.
Abdul Jabbar. Ali Bin AB; Naeem. Unaiza U; Zulfiqar. Kalsoom K; Ahmed. Shahnoor S; Hinkamp. Colin C;...
A new look at the SURMOUNT-5 study shows that tirzepatide, a drug already used for weight loss, cuts long‑term heart disease risk even more than semaglutide in people who are obese but don’t have diabetes. This suggests tirzepatide could be a powerful tool for biohackers aiming to improve heart health while losing weight.
Mamas. Mamas A MA; Bays. Harold H; Li. Runjia R; Upadhyay. Navneet N; Irani. Tanya T; Senyucel. Cagr...
In a study of people with obesity but no diabetes, weekly injections of tirzepatide (10‑15 mg) cut the predicted 10‑year heart disease risk more than semaglutide (1.7‑2.4 mg). The drop in risk was about 2.4% versus 1.4% for semaglutide, which could translate to roughly 2 million fewer heart events in the U.S. over a decade.
Combining a GLP‑1 drug like tirzepatide (or semaglutide) with diet and exercise cuts about 7 kg (15 lb) off the scale and improves blood pressure, blood sugar, and cholesterol in people who are overweight or obese.
Chunduri. Shriya S; Bidaoui. Ghassan G; Hussein. Mohammad H MH; Patel. Milee M; Abdelmaksoud. Ahmed...
In people with type‑2 diabetes who had heart bypass surgery, the drug tirzepatide (which hits both GLP‑1 and GIP receptors) led to fewer strokes, heart attacks, deaths and hospital readmissions than the similar drug semaglutide. The benefits held up over three years and were strongest for brain‑related events and blood‑clot problems.
A review of recent studies shows that drugs like tirzepatide, which are already used for diabetes and weight loss, also help people with a type of heart failure (HFpEF) who are overweight. They cut body weight, lower inflammation markers, and improve heart stress signals, leading to better walking ability and quality of life, no matter how heavy the person is.
Tirzepatide is a once‑weekly injection that hits both GLP‑1 and GIP receptors, giving stronger blood‑sugar drops and more weight loss than semaglutide or insulin in dose‑dependent studies (5, 10, 15 mg). Side effects are mainly stomach‑related early on, so a slow 4‑week titration is advised. In Belgium it’s reimbursed for people with BMI ≥ 30 and HbA1c > 7.5% on metformin, matching GLP‑1 rules but a bit stricter than EU label.
Gandhi. Ayush A; Bhatt. Nilay N; Parhizgar. Alireza A
A big US safety database looked at kidney injury reports for two popular diabetes drugs, tirzepatide and semaglutide. It found that kidney injury was reported about half as often with tirzepatide (0.47% of reports) compared to semaglutide (1.07%). The study can’t prove cause and effect, but it suggests tirzepatide may be gentler on the kidneys.
Tirzepatide, a drug that helps you lose weight by hitting two gut hormones, can slightly improve sleep apnea numbers because you drop a few pounds. However, it doesn't fix the airway blockage itself, the benefits may disappear if you stop the drug, and it can cause stomach upset or, rarely, pancreas problems. So it’s best used alongside proven tools like CPAP, not as a solo cure.
Liu. Zhao Z; Yu. Shanshan S; Jin. Xinyan X; Sheng. Luguang L; YanMu. Mai Re MR; Gao. Jie J; Lu. Jun...
The review explains how drugs that mimic the gut hormones GLP‑1 and GIP (like tirzepatide) work to boost insulin, curb appetite, and slow stomach emptying, which helps lower blood sugar and cut weight. It also points out early signs that these drugs might protect the heart, brain, and mood. While the paper is a broad overview rather than a new experiment, it gives biohackers a clear picture of why dual‑acting drugs could be more powerful than GLP‑1‑only meds.
Levine. Jake J; Lee. Yao An YA; Pham. Angela A; Guo. Jingchuan J; Dai. Hao H; Radwan. Rotana M RM; B...
A study looked at people who are overweight and have inflammatory bowel disease (IBD) and took GLP‑1 drugs like liraglutide, semaglutide, or tirzepatide. Overall, these drugs didn’t change hospital stays or surgery rates, but semaglutide seemed to cut the chance of needing IBD‑related surgery. Tirzepatide didn’t show a clear benefit, likely because only a few people used it. The medicines lowered inflammation markers and were generally safe, though Black patients on GLP‑1 drugs had a higher risk of any hospital admission.
Scientists used tiny particles from milk to carry the diabetes drugs semaglutide and tirzepatide into the gut, letting them work when taken as a pill in mice. The approach lowered blood sugar in diabetic mice, showing that oral delivery of these peptides might be possible without injections.
In mice, activating the GIP receptor (like tirzepatide does) helped control blood sugar and, in obese mice, lowered food intake and weight, while blocking the receptor also cut appetite but made insulin work worse. Both drugs raised liver fat a bit, and neither changed bone markers.
In a large real‑world study of people with overweight or obesity, those who took tirzepatide had about half the risk of reporting suicidal thoughts or attempts compared with people using other weight‑loss drugs. The data come from electronic health records, and while the study can’t prove cause and effect, it suggests tirzepatide may be safer for mental health than some alternatives.
The paper reviews how tirzepatide, a drug that activates both GLP‑1 and GIP receptors, helps lower blood sugar and cut weight better than drugs that hit just one target. It also looks at other heart‑and‑metabolism targets and suggests that future medicines could hit several of them at once, which might simplify treatment and improve heart health.
In a mouse study, the diabetes drug tirzepatide dramatically lowered liver fat, inflammation, and scarring, especially in animals that mimicked post‑menopausal hormone loss. It worked by re‑activating energy‑sensing pathways (AMPK) and dialing down growth signals (mTOR), helping the liver burn fat instead of storing it. While the results are promising, they come from rodents, so human effects—especially for women after menopause—still need confirmation.
A big real‑world study found that people who start tirzepatide (a new weight‑loss/diabetes drug) have about a 40‑50% higher chance of developing osteoporosis or breaking a bone compared with those taking other GLP‑1 drugs. The risk shows up within roughly a year of starting the medication.
Both semaglutide and tirzepatide, popular drugs for diabetes and weight loss, can sometimes cause weird skin sensations like pain from light touch (allodynia) or abnormal feelings (dysesthesia). These side effects seem to get worse at higher doses but usually go away after stopping the drug, often within a few weeks.